Clinical Relevance of Trace Bands on Serum Electrophoresis in Patients Without a History of Gammopathy.
Serum protein electrophoresis (SPE) and immunofixation is commonly used to screen for plasma cell dyscrasias. Interpretation of these tests is qualitative by nature and can yield trace, faint, or scarcely visible immunoglobulin bands (TFS), which can be difficult to classify. Whether these bands should be reported at all is challenging given their unknown clinical significance. In the present study, we retrospectively analyzed 14,036 physician-ordered protein SPE and immunofixation electrophoresis (IFE) tests on serum and urine specimens (from 4,091 patients) during the period of 2000-2010. We found that 17% of all IFE results evaluated for the presence of monoclonal gammopathies (2,389 out of 14,036) contained TFS bands, representing 4.2% (173 out of 4091) of all patients evaluated. Sixty of these patients (42%) had no previous history of gammopathy, and were clinically evaluated over a mean period of up to five years from the original diagnosis of plasma cell pathology. None of these patients had progressed to multiple myeloma, lymphoplasmacytic lymphoma, plasmacytoma, or leukemia. The remaining 82 patients (58%) had a previous history of gammopathy, but had not progressed to any symptomatic plasma cell dyscrasia. Evaluation of these patients was followed for a median period of 4.3 years, with a mean of 21.5 IFE tests per individual. These data suggest that for patients without a previous history of gammopathy, the presence of TFS bands on serum protein electrophoresis does not warrant frequent follow up investigation as commonly practiced. Routine follow up of patients with a prior history of gammopathy, conversely, are warranted and may contribute to overall survival with multiple treatment options now available. For those interpreting IFE results, it may be worth considering these data when composing comments regarding suggested repeat testing frequency by SPE/IFE or alternate test methods.
Hypertension and Vascular Research Center, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem , NC, USA.
TanYa M
TM
Gwathmey
University of North Carolina , Department of Pathology & Laboratory Medicine, Chapel Hill, NC, USA.
Monte S
MS
Willis
University of North Carolina , School of Medicine, Chapel Hill, NC, USA.
Jason
J
Tatreau
University of North Carolina , Department of Internal Medicine, Chapel Hill, NC, USA.
Shaobin
S
Wang
The Ottawa Hospital , General Campus Pathology & Laboratory Medicine, Ottawa, ON, Canada.
Christopher R
CR
McCudden
MGUS; faint; immunofixation; protein electrophoresis; serum; suspicious; trace; urine
Clin Chem. 2001 Jan;47(1):110-7
11148185
Leukemia. 2012 Apr;26(4):609-14
22193966
Curr Hematol Malig Rep. 2010 Apr;5(2):62-9
20425398
Clin Lab. 2006;52(1-2):19-27
16506360
Leukemia. 2010 Jun;24(6):1121-7
20410922
Acta Med Scand. 1966 Feb;179(2):235-47
4160039
Clin Chem Lab Med. 2006;44(5):609-11
16681432
J Cancer. 2014 Mar 11;5(3):248-52
24665349
Am J Med. 1998 May;104(5):439-44
9626026
Br J Haematol. 1994 Jun;87(2):266-72
7947266
Blood. 2006 Oct 15;108(8):2520-30
16794250
N Engl J Med. 2002 Feb 21;346(8):564-9
11856795
Clin Biochem. 2013 Feb;46(3):255-8
23127385
N Engl J Med. 2010 Nov 25;363(22):2091-101
21105791
Arch Pathol Lab Med. 1999 Feb;123(2):126-32
10050785
Clin Chem. 2010 Dec;56(12):1897-9
20940329